Alerta

METHODS OF DETERMINING GLUCOSE HYPOMETABOLISM-INDUCED ENERGY CRISIS AND TREATMENTS THEREOF

Resumen de: WO2026207251A1

The present disclosure provides systems, methods, compositions, and algorithms for treating a subject diagnosed with a glucose hypometabolic disorder (e.g., Alzheimer's disease, Parkinson's disease, or heart failure).

ELECTRICAL METABOLICS

Resumen de: WO2026202693A1

A system, device, and method for treating a diabetic condition are provided. An illustrative device includes: a lead connectable to a signal generator and including a plurality of electrodes, wherein the plurality of electrodes generate a stimulation signal according to an input received from the signal generator and deliver the stimulation signal to one or more anatomical elements of a patient to treat at least one aspect of a diabetic condition based on a closed feedback loop.

DETERMINING GLUCOSE SENSITIVITY OF GLUCOSE SENSOR AND MEASURING GLUCOSE WITH IMPLANTABLE CGM

Resumen de: US20260294287A1

A continuous glucose monitor (CGM) sensor includes a glucose oxidation electrode and a counter electrode, and does not include a glucose-specific enzyme. The glucose oxidation electrode includes a nanoporous layer comprising metal nanoparticles. The CGM sensor generates an electrical signal indicative glucose oxidation in a liquid containing glucose, which has a correlation with an effective surface area of the metal nanoparticles in the nanoporous layer. When the CGM sensor is implanted in a subject's body, an AC voltage is applied between the glucose oxidation electrode and the counter electrode, and impedance is obtained. A glucose level for the subject is determined using the impedance without use of information or data related to glucose sensitivity of a sensor or sensors over use or time.

CONTINUOUS ANALYTE MONITORING SYSTEM WITH MICRONEEDLE ARRAY

Resumen de: US20260294345A1

Described herein are variations of an analyte monitoring system, including an analyte monitoring device. For example, an analyte monitoring device may include an implantable microneedle array for use in measuring one or more analytes (e.g., glucose), such as in a continuous manner. The microneedle array may include, for example, at least one microneedle including a tapered distal portion having an insulated distal apex, and an electrode on a surface of the tapered distal portion located proximal to the insulated distal apex. At least some of the microneedles may be electrically isolated such that one or more electrodes is individually addressable.

APPLICATOR FOR CONTINUOUS BLOOD GLUCOSE MEASUREMENT DEVICE

Resumen de: US20260294290A1

According to the present disclosure, an applicator for a continuous blood glucose measurement device, the applicator being operated by attaching a body attachment unit to the body of a user, the body attachment unit including a sensor member which is inserted into the body of the user in order to measure the blood glucose, comprises: a main case; a plunger to which the body attachment unit is detachably coupled and which is installed in the main case to be movable from a first position to a second position so that the body attachment unit can be discharged to the outer direction of the main case; a needle which is detachably coupled to the body attachment unit so as to be inserted into the body of the user along with the sensor member; and a needle separating unit which separates the needle from the body of the user by moving the needle in the direction opposite to the discharge direction of the plunger, wherein the needle separating unit includes a locking unit which can be assembled with the plunger in the manner of being engaged with one side of the plunger.

CELL PRESERVATION SOLUTION AND CELL PRESERVATION METHOD

Resumen de: US20260297540A1

0000 One aspect of the embodiments relates to a cell preservation solution, comprising: 20 mM~50 mM of sucrose; 20 mM~50 mM of mannitol, 10 mM~50 mM of lactobionic acid, 5 mM~20 mM of glucose, 1 mM~3 mM of adenosine, 1 mM~5 mM of reduced glutathione, 1 mM~2 mM of dextran-40, 10 mM~30 mM of potassium dihydrogen phosphate, 10 mM~30 mM of potassium carbonate, 10 mM~30 mM of potassium chloride, 5 mM~30 mM of sodium chloride, 10 mM~60 mM of sodium hydroxide, 10 mM~60 mM of potassium hydroxide, 0 mM~20 mM of vitamin E, 0 mM~25 mM of 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid, and 0%~10% dimethyl sulfoxide. Another aspect of the embodiments relates to a cell preservation method, which uses the cell preservation solutions described in the present application to store cells.

METHOD FOR STRUCTURING AND CLASSIFICATION OF CONTINUOUS GLUCOSE MONITORING (CGM) PROFILES

Resumen de: US20260294352A1

0000 Embodiment relate to a system for developing a model to classify continuous glucose monitoring (CGM) data. The system includes a processor and computer memory having instructions stored thereon that when executed will cause the processor to determine whether two CGM profiles match based on a similarity of shapes of the two CGM profiles, each CGM profile including a data set of CGM measurements. The processor designates two matching CGM profiles as a CGM profile pair. The processor transforms the CGM profile pair into a motif. The processor labels the motif as a labelled motif based on a clinical characteristic. The processor recursively repeats the determine, designate and transform steps of a CGM profile pairing process until a finite set of motifs is created, which includes the labelled motif as a classified data point. The processor monitor, analyzes, or influences a concentration of glucose levels in a fluid.

SYSTEM AND METHOD OF MODIFYING USER PROFILE IN AUTOMATED INSULIN DELIVERY

Resumen de: US20260295160A1

Disclosed herein are systems and methods for automated insulin delivery that provide for adaptive closed loop control that can modify the stored basal profile used by the closed loop algorithm to better reflect the user's actual needs. Actual delivery rates calculated by the closed loop algorithm can be compared to the user's stored profile. If the differences between the actual delivery rates and the stored profile are statistically significant, the stored profile can be modified.

MEALTIME DELIVERY OF CORRECTION BOLUSES

Resumen de: US20260295161A1

Disclosed herein are techniques related to delivery of correction boluses. In some embodiments, the techniques involve obtaining data indicative of an ongoing glycemic response to a meal. The data includes glucose concentration measurements evaluated in combination with one or more insulin concentration values. The techniques further include causing delivery of one or more correction doses to at least partially counteract the ongoing glycemic response to the meal. The one or more correction doses are delivered instead of or in addition to a meal bolus delivered for the meal.

PHOTOACOUSTIC MEASUREMENT DEVICE HAVING OPTIMIZED GEOMETRY AND NON-INVASIVE BLOOD GLUCOSE MEASUREMENT DEVICE USING SAME

Resumen de: WO2026206023A1

Disclosed is a photoacoustic measurement method for quantitatively measuring components of a sample by using a laser pulse having a prescribed wavelength and an ultrasonic sensor having a prescribed frequency band. The photoacoustic measurement method may comprise the steps of, when the incident position of a laser pulse, the beam width of the laser pulse, and the relative position of an ultrasonic sensor are determined from the given frequency band of the ultrasonic sensor and the given position of a photoacoustic region in a sample: (a) oscillating the laser pulse with prescribed pulse energy and a prescribed pulse width to be incident onto the photoacoustic region in the sample; (b) detecting, by means of the ultrasonic sensor, photoacoustic waves generated in the photoacoustic region in the sample by the incident laser pulse, and acquiring sampling data by sampling the waveforms of the detected photoacoustic waves at a prescribed sampling rate; and (c) storing the sampling data. Furthermore, the distance from the photoacoustic region to the ultrasonic sensor may be determined on the basis of the wavelength of a frequency belonging to the frequency band of the ultrasonic sensor, and the beam width of the laser pulse may be determined on the basis of the half wavelength of the maximum frequency belonging to the frequency band of the ultrasonic sensor.

PHOTOACOUSTIC MEASUREMENT DEVICE HAVING REDUCED NOISE LEVEL AND NON-INVASIVE BLOOD GLUCOSE MEASUREMENT DEVICE USING SAME

Resumen de: WO2026206121A1

A photoacoustic measurement device of the present invention comprises a first housing and a second housing. The first housing accommodates a light source. The second housing accommodates an ultrasonic sensor and is in acoustic contact with the first housing. The characteristic acoustic impedance of a first material constituting the first housing is greater than the characteristic acoustic impedance of a second material constituting the second housing. The first housing further includes an opening through which light generated by the light source is emitted. The second housing further includes an optical path through which the light generated by the light source is guided. The optical path of the second housing is formed in a direction in which the light travels from the opening of the first housing.

METHODS AND SYSTEMS FOR CONTROLLING AN INFUSION PUMP

Resumen de: US20260295159A1

A system for pairing a controller and an infusion pump is disclosed. The system includes an infusion pump, a controller device and a user interface residing on both the infusion pump and the controller. The user interface includes a pairing mode for enabling wireless communication between the infusion pump and the controller device, wherein the user interface requires both the infusion pump and the controller to be in the pairing mode simultaneously. Also, a method of changing a power source in an infusion pump is disclosed. The method includes placing the infusion pump in idle mode wherein the infusion pump stops delivery. Removing the first power source from the infusion pump. Replacing the first power source with a second power source in the infusion pump, and maintaining the insulin on board during the changing of the first power source with the second power source.

METHODS AND SYSTEMS FOR PROMOTING GLUCOSE MANAGEMENT

Resumen de: US20260301941A1

0000 Methods and systems for encouraging interactions with a glucose monitoring system include incrementing a score and/or providing a reward based on a variety of different interactions with the glucose monitoring system. The interactions which improve the score may include initiating or changing displays, downloading data, setting operational parameters and other interactions that are independent of a user's glucose measurements. Encouraging these interactions can enhance success in maintaining healthy glucose concentrations.

PHOTOACOUSTIC MEASUREMENT DEVICE HAVING OPTIMIZED GEOMETRY AND NON-INVASIVE BLOOD GLUCOSE MEASUREMENT DEVICE USING SAME

Resumen de: WO2026206022A1

The present disclosure provides a photoacoustic measurement method capable of measuring a component of a sample by using photoacoustic waves generated by a laser pulse having a predetermined wavelength. The photoacoustic measurement method may comprise the steps of: oscillating a laser pulse at a predetermined pulse energy and pulse width and causing the laser pulse to be incident toward a photoacoustic generation area within the sample, with an ultrasonic sensor being disposed adjacent to the incident position of the laser pulse in accordance with a predetermined geometry defined by a beam width and incident position of the laser pulse with respect to the sample, the center of the photoacoustic generation area in the sample, and the position of the ultrasonic sensor; detecting, by the ultrasonic sensor, within a predetermined frequency band, photoacoustic waves generated by the laser pulse in the photoacoustic generation area in the sample, and sampling a waveform of the detected photoacoustic waves at a predetermined sampling rate to obtain sampling data; and storing the sampling data.

SYSTEMS, METHODS, AND DEVICES FOR AMUBLATORY MEDICAMENT ADMINISTRATION

Resumen de: US20260295150A1

0000 A method for administering medicament from a medical device includes receiving, from a sensor, a first biomarker level in a user, determining a basal rate of endogenous glucose production based on one or more biomarker levels, determining, based on the basal rate, an amount of medicament to transfer to the user, transmitting a first instruction to the medical device to deliver the amount of medicament to the user, further receiving, from the sensor, a second biomarker level in the user, adjusting the basal rate based on the first biomarker level and the second biomarker level, adjusting the amount of medicament to transfer to the user based on the adjusted basal rate, and transmitting a second instruction to the medical device to deliver the amount of medicament to the user.

CELLS, ISLETS, AND ORGANOIDS THAT EVADE IMMUNE DETECTION AND AUTOIMMUNITY, METHODS OF PRODUCTION AND USE THEREOF

Resumen de: US20260297530A1

0000 The invention features cells, islet-like cells, pancreatic islets and organoids (e.g., human islet-like organoids or HILOs), as well as cell cultures and methods that are useful for the rapid and reliable generation of cells and organoids, such as pancreatic islets and organoids, that are sustainable in vivo and that evade immune detection, rejection and autoimmunity. The invention also features methods of treating pancreatic diseases, such as type 2 diabetes, and pancreatic cancer, using the cells, islet-like cells, pancreatic islets and organoids (e.g., HILOs) that are designed to modulate the activity of immune cells that would otherwise react against them.

GROWTH FACTOR SUBSTITUENTS

Resumen de: US20260297529A1

Growth-enhancing peptides and fusion polypeptide are provided. The peptides and fusion polypeptides may be used in cell culture, in particular in the production of cultured meat, as replacement or addition to insulin. There is further provided a cell culture medium comprising at least one of the peptides or fusion polypeptides, and a method for growing cells comprising adding at least one of the peptides or polypeptides to the cell culture medium.

IN VITRO GUT MODEL USING MUCIN-ANALOGS

Resumen de: US20260297531A1

This disclosure relates to an invitro gut model, including an integral layer of intestinal epithelial cells, an artificial mucus atop the integral layer of intestinal epithelial cells, wherein the artificial mucus comprises a silk glycopolymer and optionally a silk polymer lacking sugar substituents, the artificial mucus having a degree of substitution of the silk glycopolymer, a location of substitution of the silk glycopolymer, a concentration of the silk glycopolymer, an overall polymer concentration, an overall silk polymer concentration, an optional concentration of the silk polymer lacking sugar substituents, an optional ratio by weight of the silk glycopolymer and the silk polymer lacking sugar substituents, and/or a silk glycopolymer silk backbone molecular weight is tailored to maintain the integral layer of intestinal epithelial cells for a predetermined length of time, and growth media accessible to the intestinal epithelial cells and tailored to maintain viability of the intestinal epithelial cells.

Ribosomal Remodeling in Diabetes

Resumen de: US20260295074A1

0000 This disclosure relates to ribosomal remodeling due to high glucose conditions. In some embodiments, translation of proteins in pancreatic beta-cells is altered based on the ribosomal remodeling. Means of increasing the percentage of large ribosomal subunit protein P1 (RPLP1) associated with ribosomes and/or decreasing the percentage of soluble RPLP1 in a cell to counteract effects of high glucose conditions in diabetes are disclosed.

SENSOR FOR ANALYTE MONITORING WITH DRUG-ELUTING CAPABILITIES

Resumen de: US20260294292A1

0000 A sensor (e.g., an analyte sensor) that may be implanted partially or fully within a living animal (e.g., a human) and may be used to measure an analyte (e.g., glucose or oxygen) in a medium (e.g., interstitial fluid, blood, or intraperitoneal fluid) within the animal. The sensor may include a housing including one or more indicator portions, a plurality of drug portions on opposite sides of each indicator portion, circuitry within the housing, including a sensing area, analyte indicator material, and a plurality of drug-eluting material in or on the drug portions of the exterior surface of the housing. The drug-eluting material each comprise one or more therapeutic agents that reduce deterioration of the analyte indicator material.

FOOTWEAR LINKED TO AN APPLICATION, FOR ASSISTING IN THE PREVENTION OF ULCERS BY MONITORING PLANTAR PRESSURE

Resumen de: WO2026206158A1

The present invention relates to a device for assisting in the prevention of ulcers, consisting of footwear having interchangeable cells where the plantar pressure is measured in individual areas of the sole of the foot by means of force sensors and sent via Bluetooth to be displayed in an application. The areas at risk of ulceration are thus detected and the cell is removed in order to facilitate plantar distribution, without the risk of developing diabetic foot.

METHOD, SYSTEM AND COMPUTER PROGRAM PRODUCT FOR CGM-BASED PREVENTION OF HYPOGLYCEMIA VIA HYPOGLYCEMIA RISK ASSESSMENT AND SMOOTH REDUCTION INSULIN DELIVERY

Resumen de: EP4814986A2

0001 An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.

ASSESSMENT OF PAST INSULIN DELIVERY OUTCOMES TO AUTOMATICALLY TUNE MDA SYSTEMS

Resumen de: EP4814980A2

Disclosed are techniques, devices and systems that obtain a glucose measurement history and a liquid drug delivery history. An expected drug delivery amount may be calculated based on the obtained glucose measurement history and the obtained liquid drug delivery history. A processor may calculate a plurality of respective drug delivery amounts implemented using different advisory mode algorithms. A respective advisory drug delivery amount of the plurality of respective advisory drug delivery amounts may be selected by the processor. A recommendation may be generated based on the selected respective advisory drug delivery amount.

BIOINTERFACE LAYER FOR ANALYTE SENSORS

Resumen de: EP4814115A2

Disclosed are devices for determining an analyte concentration (e.g., glucose). The devices comprise a sensor configured to generate a signal associated with a concentration of an analyte and a sensing membrane located over the sensor. The sensing membrane comprises a biointerface layer which interfaces with a biological fluid containing the analyte to be measured. The biointerface layer comprises a biointerface polymer, wherein the biointerface polymer comprises polyurethane and/or polyurea segments and one or more zwitterionic repeating units. The biointerface layer increases sensor longevity and decrease sensor inaccuracy by inhibiting accumulation of cells, proteins, and other biological species on the outermost layers of the sensor.

DISPOSABLE GLUCOSE BIOSENSOR INCLUDING AN ACTIVITY SENSOR

Nº publicación: EP4813291A2 30/09/2026

Solicitante:

VERILY LIFE SCIENCES LLC [US]
DEXCOM INC [US]
Verily Life Sciences LLC
DexCom, Inc.

Resumen de: EP4813291A2

0001 Example disposable biosensor devices having an activity sensor are disclosed. One example device includes a disposable biosensor that has a first electrode having a distal end to be inserted into a subcutaneous layer beneath a person's skin, the first electrode having a reactive material disposed on the distal end, and a second electrode. The disposable biosensor device also includes an activity sensor that can be activated upon an activity by the person, the activity sensor for detecting the activity and providing data about the activity. The disposable biosensor also includes a radio frequency transmitter for transmitting data obtained from the first or second electrode and the activity sensor.